Histochem Cell Biol (2008) 130:465–471 DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD (2008) InXuence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and Xuorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol 26:2364–2372 Fischer EH, Krebs EG (1955) Conversion of phosphorylase b to phos- phorylase a in muscle extracts. J Biol Chem 216:121–132 Houben R, Vetter-Kauczok CS, Ortmann S, Rapp UR, Broecker EB, Becker JC (2008) Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J Invest Dermatol Hudelist G, Kostler WJ, Czerwenka K, Kubista E, Attems J, Muller R, Gschwantler-Kaulich D, Manavi M, Huber I, Hoschutzky H, Zielinski CC, Singer CF (2006) Her-2/neu and EGFR tyrosine kinase activation predict the eYcacy of trastuzumab-based therapy in patients with metastatic breast cancer. Int J Cancer 118:1126–1134 Jendrossek V, Henkel M, Hennenlotter J, Vogel U, Ganswindt U, Muller I, Handrick R, Anastasiadis AG, Kuczyk M, Stenzl A, Bel- ka C (2008) Analysis of complex protein kinase B signalling path- ways in human prostate cancer samples. BJU Int Keese M, Magdeburg RJ, Herzog T, Hasenberg T, OVterdinger M, Pepperkok R, Sturm JW, Bastiaens PI (2005) Imaging epidermal growth factor receptor phosphorylation in human colorectal can- cer cells and human tissues. J Biol Chem 280:27826–27831 Kong A, Leboucher P, Leek R, Calleja V, Winter S, Harris A, Parker PJ, Larijani B (2006) Prognostic value of an activation state mark- er for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Res 66:2834–2843 Kuo RC, Lin CY, Kuo MY (2006) Prognostic role of c-Jun activation in patients with areca quid chewing-related oral squamous cell carcinomas in Taiwan. J Formos Med Assoc 105:229–234 Kuwai T, Nakamura T, Sasaki T, Kim SJ, Fan D, Villares GJ, Zigler M, Wang H, Bar-Eli M, Kerbel RS, Fidler IJ (2008) Phosphory- lated epidermal growth factor receptor on tumor-associated endo- thelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia 10:489–500 Loprevite M, Tiseo M, Chiaramondia M, Capelletti M, Bozzetti C, Bortesi B, Naldi N, Nizzoli R, Dadati P, Kunkl A, Zennaro D, Lagrasta C, Campanini N, Spiritelli E, Camisa R, Grossi F, Rindi G, Franciosi V, Ardizzoni A (2007) Buccal mucosa cells as in vivo model to evaluate geWtinib activity in patients with advanced non small cell lung cancer. Clin Cancer Res 13:6518–6526 Mandell JW (2003) Phosphorylation state-speciWc antibodies: applica- tions in investigative and diagnostic pathology. Am J Pathol 163:1687–1698 Mandell JW, Banker GA (1996) A spatial gradient of tau protein phos- phorylation in nascent axons. J Neurosci 16:5727–5740 Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912–1934 Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN, Papadimitrakopoulou VA (2005) Akt activation correlates with adverse outcome in tongue cancer. Cancer 104:2430–2436 471 Matsumoto M, Furihata M, Kurabayashi A, Ohtsuki Y (2004) Phos- phorylation state of tumor-suppressor gene p53 product overex- pressed in skin tumors. Oncol Rep 12:1039–1043 McCall P, Gemmell LK, Mukherjee R, Bartlett JM, Edwards J (2008) Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer 98:1094–1101 Nairn AC, Detre JA, Casnellie JE, Greengard P (1982) Serum antibod- ies that distinguish between the phospho- and dephospho-forms of a phosphoprotein. Nature 299:734–736 Nieto Y, Nawaz F, Jones RB, Shpall EJ, Nawaz S (2007) Prognostic signiWcance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EG- FRvIII in locoregionally advanced breast cancer. J Clin Oncol 25:4405–4413 Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O’To- ole T, Gibbons J, Belldegrun AS, Figlin RA (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma: implica- tions for molecular patient selection for targeted therapy. Cancer 109:2257–2267 Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barker FG 3rd, Ful- ler GN, Aldape KD (2006) Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblas- toma. Clin Cancer Res 12:3935–3941 Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG 2nd, Buckner JC, James CD, Aldape K (2007) Epidermal growth factor receptor variant III status deWnes clinically distinct subtypes of glioblas- toma. J Clin Oncol 25:2288–2294 Pozner-Moulis S, Cregger M, Camp RL, Rimm DL (2007) Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab Invest 87:251–260 Puhringer-Oppermann F, Stahl M, Keller G, Sarbia M (2006) Lack of prognostic impact of p53 gene mutation and p53 phosphorylation at serine 15 in multimodally treated adenocarcinomas of the gas- troesophageal junction. J Cancer Res Clin Oncol 132:433–438 Roskelley CD, Bissell MJ (2002) The dominance of the microenviron- ment in breast and ovarian cancer. Semin Cancer Biol 12:97–104 Schmitz KJ, Otterbach F, Callies R, Levkau B, Holscher M, HoVmann O, Grabellus F, Kimmig R, Schmid KW, Baba HA (2004) Prog- nostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol 17:15–21 Thor A (2001) HER2—a discussion of testing approaches in the USA. Ann Oncol 12(Suppl. 1):S101–S107 Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, Kobayashi S, Fujii Y, Iwase H (2008) Low phosphorylation of ER{alpha} serine 118 and high phosphorylation of ER{alpha} serine 167 improve survival in ER-positive breast cancer. Endocr Relat Cancer Yu Z, Weinberger PM, Sasaki C, Egleston BL, Speier WFT, HaVty B, Kowalski D, Camp R, Rimm D, Vairaktaris E, Burtness B, Psyrri A (2007) Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer. Cancer Epide- miol Biomarkers Prev 16:553–558 123